Alkermes plc. (NASDAQ:ALKS)
| Market Cap | 6.60B+24.9% |
| Revenue (ttm) | 1.67B+10.8% |
| Net Income | 66.12M-81.0% |
| EPS | 0.38-81.6% |
| Shares Out | 167.76M |
| PE Ratio | 100.12 |
| Forward PE | 73.67 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 917,584.099 |
| Open | 41.10 |
| Previous Close | 41.45 |
| Day's Range | 39.10 - 41.26 |
| 52-Week Range | 27.00 - 55.67 |
| Beta | 0.27 |
| Analysts | Buy |
| Price Target | 58.83(+49.60%) |
| Earnings Date | Oct 28, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About ALKS
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$ALKS stock is featured in our Insider Score Rankings, Congress Trading, and Insider Trades datasets.
→ All Stock ListsCongress Trading
Recent trades of ALKS by members of U.S. Congress
| Politician | Type | Traded |
|---|---|---|
| Gilbert CisnerosHouse / D | Purchase$15.00K – $50.00K | Jul 30, 2026 |
| Gilbert Ray CisnerosHouse / D | Purchase$15.00K – $50.00K | Jul 30, 2026 |
| Gilbert Ray CisnerosHouse / D | Purchase$15.00K – $50.00K | Jul 29, 2026 |
Recently reported changes in ALKS holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ALKS's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ALKS Estimated quarterly lobbying spending
Source: U.S. Senate LDA
ALKS Revenue by Segment or Geography
| Segment | Revenue | % of All |
|---|---|---|
| Product sales, net | $411.72M | 50.00% |
| VIVITROL | $124.45M | 15.11% |
| ARISTADA and ARISTADA INITIO | $96.72M | 11.75% |
| LUMRYZ | $96.57M | 11.73% |
| LYBALVI | $93.98M | 11.41% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New ALKS patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ALKS from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in ALKS
| ETF | Est. Holding Size |
|---|---|
| IJRiShares Core S&P Small-Cap ETF | $415.61M |
| VTIVanguard Morningstar Total Stock Market ETF | $249.46M |
| IWMiShares Russell 2000 ETF | $182.47M |
| VBVanguard Morningstar Small-Cap ETF | $180.22M |
| XBIState Street SPDR S&P Biotech ETF | $141.98M |
| AFTYPacer CSOP FTSE China A50 ETF | $119.66M |
Estimated from each fund’s disclosed top holdings × AUM
ALKS Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from ALKS’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score